Canada Cell and Gene Therapy Market to be Dominated by Cell Therapy Through 2028
The growing prevalence of cancer and other diseases is
expected to drive the growth of Canada cell and gene therapy market in the
forecast period, 2024-2028.
According to TechSci Research report, “Canada Cell and Gene
Therapy Market - By Region, Competition, Forecast and
Opportunities, 2018-2028”, Canada
cell and gene therapy market is anticipated to grow at an impressive rate in
the forecast period, 2024-2028. To the increase their manufacturing
capabilities, pharmaceutical companies are closely investing in their own
manufacturing facilities or outsourcing products to contract development and
manufacturing organizations across the region. Additionally, bio producers
are forming strategic partnerships with contract producers to quicken the
R&D of their candidate programs, which will escalate the growth of Canada cell
and gene therapy market in the coming years. Similarly, growing demand for
cutting-edge treatments has increased market competition among participants which
will further drive the growth of Canada cell and gene therapy market during the
forecast period.
However, While
Canada has made progress in establishing a supportive regulatory environment
for cell and gene therapies, there are still challenges related to regulatory
processes and timelines, which may hamper the Canada Cell and Gene Therapy market
growth during the forecast period. Access to cell and gene therapies and
reimbursement for these treatments pose challenges in Canada. These therapies
are often expensive due to their complex manufacturing processes and
personalized nature which may hamper the Canada Cell and Gene Therapy market
growth during the forecast period. Also, manufacturing cell and gene therapies at scale
presents significant challenges. These therapies are often personalized and
require complex and specialized manufacturing processes which can further
restrict the growth of Canada cell and gene therapy market.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Canada Cell and Gene Therapy Market”
Canada cell and gene therapy market can be
segmented by type, indication, end user, and region.
Based on type, Canada cell
and gene therapy market can be divided into cell therapy and gene therapy. The
cell therapy segment dominated Canada cell and gene therapy market in 2022 and is
expected to continue maintaining its dominance throughout the forecast period.
This can be ascribed to due to growing application of cell therapy in the
treatment of cancers, autoimmune diseases, urinary problems, and infectious
diseases along with growing availability of funding for new cell lines and
increasing organic and inorganic growth strategies by companies in the region.
Based on indication, Canada cell and gene
therapy market can be segmented into oncology diseases, cardiovascular
diseases, orthopedic diseases, neurological diseases, and others. The oncology segment is expected to dominate Canada
cell and gene therapy market during the forecast period on account of growing demand
for novel therapies for the treatment of cancer and growing availability of
gene therapy in different hospitals and research institutes.
Major companies operating in Canada cell
and gene therapy market are:
- Amgen Canada Inc
- Kolon TissueGene Inc
- Novartis Pharmaceuticals Canada Inc
- Pfizer Canada Inc
- Gilead Sciences Inc
- Bristol-Myers Squibb Canada Inc
- Merck & Co Inc
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“Canada cell and gene therapy
is expected to dominate the market during the forecast period on account due to
increasing
investments in R&D from large and small companies in the development of
ideal therapy drugs in this region. Similarly, increasing number of
investments by the government and the growing prevalence of targeted diseases
is expected to drive the growth of the Canada cell and gene therapy market
during the forecast period. Also, large population with unmet medical needs and increasing
demand for novel technologies in the treatment of rare but increasingly
prevalent diseases
will further
propel the growth of Canada cell and gene therapy market during the forecast
period. Furthermore, easy availability of resources, the local presence of
major companies, and increased investment, by the governments are the major
factors influencing the growth of the Canada cell and gene therapy market over
the years. Besides, key players are engaged in strategic initiatives to boost
their offerings in the market which is expected to create a lucrative growth of
the Canada cell and gene therapy market during the forecast period.” said Mr.
Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Canada
Cell and Gene Therapy Market By Type (Cell Therapy, Gene Therapy), By Indication
(Oncology Diseases, Cardiovascular Diseases, Orthopedic Diseases, Neurological
Diseases, and Others), By End-Users (Hospitals & Clinics, Academic &
Research Institutions, and Others) and By Region, Competition, Forecast and
Opportunities, 2028”,
has evaluated the future growth potential of Canada cell and gene therapy
market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Canada cell and gene
therapy market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com